RecruitingPhase 1NCT07267221

Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.

Studying Fish-eye disease

Last synced from ClinicalTrials.gov May 9, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Daewoong Pharmaceutical Co. LTD.
Intervention: DWJ1622(drug)
Enrollment: 36 target
Eligibility: 19 years · All sexes
Timeline: 2025 – 2026

Study locations (1)

H Plus YANGJI Hospital, Seoul, Gwanak-gu, South Korea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07267221 on ClinicalTrials.gov

Other trials for Fish-eye disease

Additional recruiting or active studies for the same condition.

ENROLLING BY INVITATIONPHASE1NCT07239453
Clinical Trial of Comparing DA-2902 and DA-2902-R in Healthy Adult Subjects
Dong-A ST Co., Ltd.
ACTIVE NOT RECRUITINGNANCT04325308
Early Protein Supplementation in Extremely Preterm Infants Fed Human Milk
University of Alabama at Birmingham
RECRUITINGNANCT03451968
Amino Acid Metabolism in Fed Surgical Critically Ill Patients
Rabin Medical Center

See all trials for Fish-eye disease →

← Back to all trials